An interventional study of Tricuspid repair in Tricuspid Regurgitation, Mitral Regurgitation and Cardiopulmonary Bypass, sponsored by Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Nanjing Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2024, is one of 15 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 11th registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
Jiangsu Trulive Medical Co., Ltd · Sites in China
Ages 65+
Shanghai Huihe Medical Technology Co., Ltd · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Haiyan Wang · Sites in China
Ages 18+
First Hospital of China Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 129 across the 16 interventional studies, 2,320 across the 12 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 28 have an industry lead sponsor. The 10 most frequent:
Nanjing Medical University is the lead sponsor of 172 studies on the registry; 51 are open to participants now.
Nanjing Medical University has 2 studies filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Tricuspid Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07292896First Hospital of China Medical UniversityA Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography | 2026-12 |
| NCT05595187Nanjing Medical UniversityConcomitant Tricuspid Repair in Patients With Left Heart Surgery | 2026-12-31 |
| NCT05194423Changhai HospitalTHE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein | 2027-03 |
| NCT06663566Beijing Anzhen HospitalApplication of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tricuspid regurgitation is common in patients with severe left heart diseases, such as degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform concomitant tricuspid-valve repair during left heart surgery in patients who have mild tricuspid regurgitation. To inform decision making, we will conduct a multicenter, randomized trial to assess the benefits and risks of tricuspid-valve repair at the time of left heart diseases in patients with mild tricuspid regurgitation who were undergoing surgery for left heart surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tricuspid repair techniques included suture placement and the type of prosthetic annuloplasty with specified the use of an approved rigid, incomplete, nonplanar, and undersized (ranging 26, 28, or 30, 32, 34 mm) ring.
Device: Tricuspid repair
Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
A composite of adverse cardiovascular events
a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation from baseline by two grades or the presence of severe tricuspid regurgitation, or death.
Time frame: 2 years after surgery at follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2024; primary completion for Dec 2026, 31 months later.
Of 86 interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →